Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/TampvCiCIs https://t.co/y9FDVJoEaD

Metanalysis of Steroid Tx & metabolic events (118 studies & 17113 pts) showed an increased risk: - hyperglycemia 10% (esp lung dz 22%) - severe hyperglyc. 5%, HTN 6%, Wt gain 13% , hyperlipid 8% - Incr risk of hyperglyc(OR 2), HTN (1.7), Wt gain (5.2) https://t.co/E54IB3YVfn https://t.co/CPzrgIgJ12

Full read, very good review of steroids, HPA suppression, equivalents, use during surgery etc from J Endo Society. Notably literature supports continued daily GC in surgical patients, with a short course of perioperative IV GC https://t.co/jzNE5o0DBG https://t.co/6V8mhTOVTv

About 1 mo ago we reported US drug makers would increase price of 350 drugs; now it seems US Pharma has raised list prices of 983 arthritis, cancer and otherdrugs by an average of 5.6% in Jan 2023; as industry faces new federal laws to control costs https://t.co/HkdDurbNrQ https://t.co/rEvmwACdfk

Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/8R51VLUbvX https://t.co/vc3JJKXfk3

Novel Proteomic Biomarker Set in Osteoarthritis NIH funded researchers have developed a set of serum proteomic biomarkers that successfully predict clinically relevant KOA progression (both structural change and joint pain) over a 2 year period. https://t.co/4xU2bYS0xN https://t.co/Rtdr280ghe

Physician Burnout Remains, Less So in Rheumatology The 2023 Medscape Survey on Physician burnout ranks rheumatology at #10; which is down from #2 when the survey was last done in 2021. https://t.co/IsC8TQ95RH https://t.co/BBQaSUnQoj

1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/Y5KDv7wSho https://t.co/WjHVxOQ1xJ

Join us at RheumNow Live this March! Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA. https://t.co/1aUe1mk4La https://t.co/R1xRMDK6MK

Herpes Zoster with JAK Inhibitors A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids. https://t.co/rlYXJWONyS https://t.co/nwqbbp6Ci3

Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/T0rP96FM0Z https://t.co/W8NFtfevQg